Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily, with titration based on clinical response. Doses may range from 40 mg to 120 mg per day. Doses exceeding 80 mg daily should be divided and administered intravenously.
## Pediatric Dosing
* **GERD (Age 5-16 years):**
* **Healing of Erosive Esophagitis:** 20 mg or 40 mg orally once daily for up to 8 weeks. The specific dose depends on body weight and severity of esophagitis.
* **Maintenance of Healing:** 20 mg orally once daily.
* **Note:** Dosing for pediatric patients is less established for IV administration and hypersecretory conditions.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment, though caution may be advised in severe hepatic impairment.
## Contraindications
Known hypersensitivity to pantoprazole or any component of its formulation. Coadministration with rilpivirine-containing products.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common: Liver enzyme elevations, rash, urticaria, arthralgia.
## Key Drug Interactions
* **Drugs with pH-dependent absorption:** Pantoprazole can decrease absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, itraconazole, certain protease inhibitors like atazanavir).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with clopidogrel and other CYP2C19 substrates.
* **Rilpivirine:** Contraindicated due to risk of significantly increased rilpivirine levels and potential for serious adverse reactions.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Long-term use of PPIs is associated with increased risk of fractures (hip, wrist, spine), *Clostridium difficile* infection, osteoporosis, and vitamin B12 deficiency. Periodic assessment of need for therapy is recommended.
* Monitor magnesium levels, especially with prolonged use or concurrent use of other drugs that may cause hypomagnesemia (e.g., diuretics).
## Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* For IV administration, reconstitute and further dilute as per manufacturer instructions. Infusion over 15 minutes.
* IV to PO switch can be made when clinically appropriate.
---
*This information is intended for clinical decision support and does not replace the need to consult the official prescribing information and institutional protocols.*
